Effect of bepridil in patients with chronic stable angina: results of a multicenter trial.

Hill, Julie; O’Brien, John; Alpert, Joseph S.; Gore, Joel M.; Zusman, Randall M.; Christensen, Donna M.; Boucher, Charles A.; Gw, Vetrovec; Borer, Jeffrey S.; Friedman, Carola P.

doi:10.1161/01.cir.71.1.98

Cited by 27 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The double-blind, in parallel groups, multicenter study of the Bepridil Collaborative Study Group (Hill et al, 1985), compared 4 patients groups (BE at 200, 300 and 400 mg once a day and PL). The patients were randomized after a 2-week single-blind placebo and then followed up for 12 weeks.…”

Section: Discussionmentioning

confidence: 99%

Controlled Clinical Trial of Bepridil, Propranolol and Placebo in the Treatment of Exercise Induced Angina Pectoris

Destors¹,

Boissel²,

Philippon³

et al. 1989

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

191 patients with exercise induced angina pectoris and a mean weekly number of attacks of 11.3 were admitted in a multicentre double-blind study after an evaluation period on placebo. They were randomly assigned to: bepridil (100-400 mg/d), propranolol (60-240 mg/d), placebo ("strength" 100-400) and treated for 6 months. During the first 8 weeks the treatment was individually titrated. Withdrawal from the study was considered as "failure". 19.2% bepridil patients, 21.8% propanolol patients and 17.1% placebo patients stopped their study medication. Severe angina pectoris leading to withdrawal was not observed in bepridil group against 3 cases in placebo (P = 0.03) and 6 in propanolol groups (P = 0.02). In all groups the number of attacks was reduced between 49 and 77%. At wk 8, bepridil patients were improved compared with placebo patients (P = 0.04). Total work performed and duration of exercise on the ergometer were increased in bepridil patients at wk 8 compared with placebo patients. However, all treatment differences had vanished by wk 24. One patient died in the bepridil group, 2 in the propranolol group and none in the placebo group. The total numbers of fatal or severe non fatal cardiovascular events were not statistically significantly different. There were less severe adverse cardiovascular reactions in the bepridil group than in the propranolol group (P less than 0.03).

show abstract

Section: Discussionmentioning

confidence: 99%

Controlled Clinical Trial of Bepridil, Propranolol and Placebo in the Treatment of Exercise Induced Angina Pectoris

Destors¹,

Boissel²,

Philippon³

et al. 1989

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Bepridil also functions in exercise-induced myocardial ischemia and angina pectoris. The clinical experimental results, on the other hand, revealed dizziness, liver dysfunction, and even death cases (Hill et al 1985 ). The most typical event is multiple patients resulting in bepridil-induced pulmonary toxicity, which directly led to the suspension of bepridil in the USA (Gaku et al 2003 ; Suzuki et al 2009 ; Watanabe et al 2009 ).…”

Section: Introductionmentioning

confidence: 99%

Effects of bepridil on early cardiac development of zebrafish

Wei

Lei

et al. 2022

Cell Tissue Res

View full text Add to dashboard Cite

Bepridil is a commonly used medication for arrhythmia and heart failure. It primarily exerts hemodynamic effects by inhibiting Na + /K + movement and regulating the Na + /Ca 2+ exchange. In comparison to other Ca 2+ inhibitors, bepridil has a long half-life and a complex pharmacology. Additionally, it is widely used in antiviral research and the treatment of various diseases. However, the toxicity of this compound and its other possible effects on embryonic development are unknown. In this study, we investigated the toxicity of bepridil on rat myocardial H9c2 cells. After treatment with bepridil, the cells became overloaded with Ca 2+ and entered a state of cytoplasmic vacuolization and nuclear abnormality. Bepridil treatment resulted in several morphological abnormalities in zebrafish embryo models, including pericardium enlargement, yolk sac swelling, and growth stunting. The hemodynamic effects on fetal development resulted in abnormal cardiovascular circulation and myocardial weakness. After inhibiting the Ca 2+ transmembrane, the liver of zebrafish larvae also displayed an ectopic and deficient spatial location. Additionally, the results of the RNA-seq analysis revealed the detailed gene expression profiles and metabolic responses to bepridil treatment in zebrafish embryonic development. Taken together, our study provides an important evaluation of antiarrhythmic agents for clinical use in prenatal heart patients. Supplementary Information The online version contains supplementary material available at 10.1007/s00441-022-03706-w.

show abstract

Chemische Struktur und Pharmakokinetik der Calcium-Antagonisten

Lydtin

Trenkwalder

1988

Calcium-Antagonisten

View full text Add to dashboard Cite

Effect of bepridil in patients with chronic stable angina: results of a multicenter trial.

Cited by 27 publications

References 8 publications

Controlled Clinical Trial of Bepridil, Propranolol and Placebo in the Treatment of Exercise Induced Angina Pectoris

Controlled Clinical Trial of Bepridil, Propranolol and Placebo in the Treatment of Exercise Induced Angina Pectoris

Effects of bepridil on early cardiac development of zebrafish

Chemische Struktur und Pharmakokinetik der Calcium-Antagonisten

Contact Info

Product

Resources

About